Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 4/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531518 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531344 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531329 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531605 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531606 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL13905492 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL17366579 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL10086303 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL13905501 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL10260659 | 0.91 | CETP (0.43) | CETPNR1I2SCN5ATACR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943474-B1 | BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXENE DERIVATIVE COMPOUNDS AS CETP INHIBITORS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-07-05 | — | — | EP | disclosed |
| US-9493430-B2 | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20160237046-A9 | Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-08-18 | — | — | US | disclosed |
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20150322023-A1 | Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors | CHONG KUN DANG PHARM CORP (KR) | 2015-11-12 | — | — | US | disclosed |
| WO-2014119947-A1 | BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXENE DERIVATIVE COMPOUNDS AS CETP INHIBITORS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090075979-A1 | CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| WO-2009027785-A2 | 1, 3-OXAZOLE DERIVATIVES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20090075979-A1 | CETP Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 56/4885SCN5A 3946/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20160237046-A9 | Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors | CETP, LIPC, PCSK9 | CETP 1/4885NR1I2 83/4885SCN5A 2875/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20150322023-A1 | Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors | CETP, LIPC, PCSK9 | CETP 1/4885NR1I2 83/4885SCN5A 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.